Belzutifan

The adjuvant VEGF TKI studies were largely negative.

The Belzutifan adjuvant trial was positive for PFS.

Does that...

But we kind of feel...

without toxicity but if the drug has toxicity because we're combining it with other it means we're not giving the drug so it doesn't matter here

okay tony i've got another question for you if i may and we're going to come into your data in a second but i want you to solve or try and address this for me so the EPO suppression appears to be important.

The dosing of Belzutifan was chosen off erythropoietin suppression, which was about 60%.

Erythropoietin did seem to bounce back in those trials.